By Kim Richters
Sanofi SA said Thursday that the European Patent Office had ruled in favor of Sanofi and Regeneron Pharmaceuticals Inc. in a patent case related to their cholesterol drug Praluent.
The French pharmaceutical company said the European authority's ruling invalidated certain European patent claims made by Amgen Inc. concerning PCSK9 antibodies relevant to the drug.
U.S. pharmaceutical company Amgen wasn't immediately available for comment.
Sanofi said it owns the rights for the drug outside of the U.S., while Regeneron holds them inside the country.
Praluent continues to be on the market in the European countries where it is approved, with the exception of Germany following an injunction in July last year, which Sanofi said it has appealed.
Write to Kim Richters at firstname.lastname@example.org
(END) Dow Jones Newswires
October 29, 2020 10:43 ET (14:43 GMT)Copyright (c) 2020 Dow Jones & Company, Inc.